pharmaphorum

OCTOBER 22, 2020

AT-527 works by blocking the viral RNA polymerase enzyme needed for viral replication. ” Roche has been studying its already-approved anti-inflammatory drug Actemra (tocilizumab), branded as RoActemra in some countries, to see if it can cut the chances of COVID patients needing a ventilator.

Development 66

Development Branding RNA Manufacturing 66

XTalks

FEBRUARY 3, 2022

The company is investing $1 billion of the budget into a brand-new manufacturing facility in Concord, North Carolina in the US. The anti-amyloid antibody will go head-to-head against Biogen’s Aduhelm (aducanumab), which continues to face controversy over its approval given questions about its lacklustre clinical benefit.

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

pharmaphorum

DECEMBER 21, 2020

The European Commission has already approved the drug under the brand name Leqvio earlier this month following backing from the CHMP regulatory committee. The FDA has not yet conducted a facility inspection and the FDA will set out a schedule if it deems one necessary, once safe travel may resume.

Drugs 52

Drugs RNA Manufacturing Licensing 52

XTalks

JANUARY 25, 2021

Although TaiMed Biologics’ antibody drug Trogarzo is an intravenous formulation that is administered once every 14 days, it must be used in conjunction with other antiretroviral drugs. Patients in the studies were virologically suppressed (HIV-1 RNA less than 50 copies/milliliter) prior to initiation of treatment with Cabenuva.

FDA Approval 52

FDA Approval Trials Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic. Download this exclusive report here.

Vaccine 52

Vaccine Vaccination Protein Immune Response 52

pharmaphorum

APRIL 28, 2022

But the company was inspired to re-brand its rare disease business unit as a response to internal ramp-ups that have occurred over the last few years, Helfgott said. Plus, many of these small players are very good at research, not necessarily at developing or commercialising their brands,” he said.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

XTalks

AUGUST 30, 2022

Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. Biogen’s nusinersen (brand name Spinraza) is an antisense oligonucleotide (ASO) therapy that is administered directly into the CNS by intrathecal injection through lumbar puncture.

Trials 83

Trials Drug Delivery Drugs Gene 83